招银国际发表研究报告指,三生制药(01530.HK) 将PD-1/VEGF双抗(SSGJ-707)的中国以外权益授予辉瑞(PFE.US) ,将获得12.5亿美元的首付款及最高达48亿美元的里程碑付款,并将获得双位数的产品销售分成,交易规模大幅超出市场预期。公司将保留707在中国的权益,而辉瑞将拥有707在中国商业化的选择权。此外,授权交易达成后,辉瑞还将以30日成交量加权平均价认购公司1亿美元的...
Source Link招银国际发表研究报告指,三生制药(01530.HK) 将PD-1/VEGF双抗(SSGJ-707)的中国以外权益授予辉瑞(PFE.US) ,将获得12.5亿美元的首付款及最高达48亿美元的里程碑付款,并将获得双位数的产品销售分成,交易规模大幅超出市场预期。公司将保留707在中国的权益,而辉瑞将拥有707在中国商业化的选择权。此外,授权交易达成后,辉瑞还将以30日成交量加权平均价认购公司1亿美元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.